Clinical trials: SGLT2 Inhibitor
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Diabetes Mellitus, Type 2
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
- Trial name
- NCT03817463
- Testing
- Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Where
- 13 sites in Denmark, Finland and 9 more
- Volunteers
- 327,624 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets
- Trial name
- STELLALONGTERM (NCT02479399)
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 11,412 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease, Type 2 Diabetes
An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results
This is an observational study, in which data from the past of people with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FLAMINGO (NCT05640180)
- Testing
- Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
- Where
- United States
- Volunteers
- 17,847 people
- Sponsor
- Bayer
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
The objective of this study is to assess the reduction in insulin dose from baseline at Week 24 while keeping the blood glucose levels controlled (maintaining HbA1c values) when ipragliflozin is administered once daily for 24…
- Trial name
- NCT02847091
- Testing
- Ipragliflozin, Insulin
- Where
- 15 sites in Japan
- Volunteers
- 103 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2…
- Trial name
- NCT06688123
- Testing
- SHR-3167, Insulin glargine
- Where
- 2 sites in China
- Volunteers
- 275 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Type 2 Diabetes
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2…
- Trial name
- TELOS (NCT06972732)
- Testing
- Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 1 Diabetes Mellitus
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
The objective of this study is to confirm efficacy of ASP1941 based on the changes in HbA1c and to assess its safety in subjects with type 1 diabetes mellitus receiving ASP1941 once daily in combination with insulin for 24 weeks.
- Trial name
- NCT02897219
- Testing
- ipragliflozin, Insulin Therapy
- Where
- 36 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus (DM)
A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
This study will evaluate whether VCT220 tablets improve blood glucose control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with lifestyle intervention alone, metformin alone, or metformin…
- Trial name
- VICTOR-DM (NCT07872436)
- Testing
- VCT220 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Vincentage Pharma Co., Ltd
Type 2 Diabetes Mellitus (T2DM)
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Metformin Monotherapy or in Combination with…
- Trial name
- Optimum 2 (NCT06778967)
- Testing
- GZR18, semaglutide
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject
- Trial name
- NCT05266404
- Testing
- Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca